Abstract
Cenobamate is a new antiseizure medication (ASM) approved in the US for uncontrolled focal (partial-onset) seizures in adults. Two international, double-blind, placebo-controlled trials (C013/C017) demonstrated cenobamate efficacy and safety. Here we report time to onset of efficacy during titration of cenobamate in these studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
